Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $25.37, for a total value of $190,275.00. Following the completion of the transaction, the insider owned 10,503 shares in the company, valued at approximately $266,461.11. The trade was a 41.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Stock Performance

NASDAQ:MAZE traded up $0.69 during trading hours on Friday, reaching $27.27. The stock had a trading volume of 860,494 shares, compared to its average volume of 755,305. The stock has a market cap of $1.36 billion, a P/E ratio of -8.44 and a beta of 5.16. The stock has a 50 day simple moving average of $36.92 and a 200 day simple moving average of $38.05. Maze Therapeutics, Inc. has a 12-month low of $8.24 and a 12-month high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. On average, equities analysts expect that Maze Therapeutics, Inc. will post -2.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on MAZE. JPMorgan Chase & Co. increased their target price on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. HC Wainwright lifted their price objective on shares of Maze Therapeutics from $60.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. BTIG Research reissued a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a report on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Maze Therapeutics currently has a consensus rating of “Buy” and an average target price of $66.00.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Maze Therapeutics during the first quarter worth about $57,000. Goldman Sachs Group Inc. purchased a new stake in Maze Therapeutics in the first quarter valued at approximately $145,000. Rhumbline Advisers bought a new stake in Maze Therapeutics during the first quarter valued at approximately $80,000. Geode Capital Management LLC grew its stake in Maze Therapeutics by 8.8% in the 2nd quarter. Geode Capital Management LLC now owns 231,237 shares of the company’s stock worth $2,838,000 after buying an additional 18,773 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Maze Therapeutics by 387.0% in the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after buying an additional 3,371 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.